Baird Medical Investment (BDMD) Competitors $1.64 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.06 (-3.72%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDMD vs. SGHT, PROF, ELMD, OBIO, and RXSTShould you buy Baird Medical Investment stock or one of its competitors? MarketBeat compares Baird Medical Investment with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Baird Medical Investment include Sight Sciences (SGHT), Profound Medical (PROF), Electromed (ELMD), Orchestra BioMed (OBIO), and RxSight (RXST). These companies are all part of the "medical equipment" industry. BDMD vs. SGHTBDMD vs. PROFBDMD vs. ELMDBDMD vs. OBIOBDMD vs. RXSTHow does Baird Medical Investment compare to Sight Sciences?Baird Medical Investment (NASDAQ:BDMD) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Which has more risk & volatility, BDMD or SGHT? Baird Medical Investment has a beta of -1.18, suggesting that its stock price is 218% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Which has preferable valuation and earnings, BDMD or SGHT? Baird Medical Investment has higher earnings, but lower revenue than Sight Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBaird Medical Investment$22.54M2.98N/AN/AN/ASight Sciences$77.36M3.32-$38.43M-$0.71N/A Does the media prefer BDMD or SGHT? In the previous week, Sight Sciences had 3 more articles in the media than Baird Medical Investment. MarketBeat recorded 3 mentions for Sight Sciences and 0 mentions for Baird Medical Investment. Sight Sciences' average media sentiment score of 0.73 beat Baird Medical Investment's score of 0.00 indicating that Sight Sciences is being referred to more favorably in the news media. Company Overall Sentiment Baird Medical Investment Neutral Sight Sciences Positive Do institutionals and insiders have more ownership in BDMD or SGHT? 19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is BDMD or SGHT more profitable? Baird Medical Investment has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Baird Medical Investment's return on equity of 0.00% beat Sight Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Baird Medical InvestmentN/A N/A N/A Sight Sciences -46.83%-52.34%-28.49% Do analysts recommend BDMD or SGHT? Sight Sciences has a consensus price target of $8.31, suggesting a potential upside of 76.11%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Sight Sciences is more favorable than Baird Medical Investment.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Sight Sciences 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 SummarySight Sciences beats Baird Medical Investment on 9 of the 13 factors compared between the two stocks.How does Baird Medical Investment compare to Profound Medical?Baird Medical Investment (NASDAQ:BDMD) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, BDMD or PROF? Baird Medical Investment has higher revenue and earnings than Profound Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBaird Medical Investment$22.54M2.98N/AN/AN/AProfound Medical$16.10M15.19-$42.57M-$1.24N/A Is BDMD or PROF more profitable? Baird Medical Investment has a net margin of 0.00% compared to Profound Medical's net margin of -206.76%. Baird Medical Investment's return on equity of 0.00% beat Profound Medical's return on equity.Company Net Margins Return on Equity Return on Assets Baird Medical InvestmentN/A N/A N/A Profound Medical -206.76%-78.88%-64.06% Does the media refer more to BDMD or PROF? In the previous week, Profound Medical had 2 more articles in the media than Baird Medical Investment. MarketBeat recorded 2 mentions for Profound Medical and 0 mentions for Baird Medical Investment. Profound Medical's average media sentiment score of 0.60 beat Baird Medical Investment's score of 0.00 indicating that Profound Medical is being referred to more favorably in the news media. Company Overall Sentiment Baird Medical Investment Neutral Profound Medical Positive Do institutionals & insiders hold more shares of BDMD or PROF? 19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, BDMD or PROF? Baird Medical Investment has a beta of -1.18, meaning that its stock price is 218% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Do analysts rate BDMD or PROF? Profound Medical has a consensus target price of $12.00, indicating a potential upside of 78.31%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Baird Medical Investment.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryProfound Medical beats Baird Medical Investment on 8 of the 13 factors compared between the two stocks.How does Baird Medical Investment compare to Electromed?Electromed (NYSE:ELMD) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Do insiders & institutionals believe in ELMD or BDMD? 40.8% of Electromed shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 10.5% of Electromed shares are held by insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ELMD or BDMD more profitable? Electromed has a net margin of 11.34% compared to Baird Medical Investment's net margin of 0.00%. Electromed's return on equity of 15.71% beat Baird Medical Investment's return on equity.Company Net Margins Return on Equity Return on Assets Electromed11.34% 15.71% 13.37% Baird Medical Investment N/A N/A N/A Do analysts rate ELMD or BDMD? Electromed currently has a consensus price target of $37.50, indicating a potential downside of 2.27%. Given Electromed's stronger consensus rating and higher probable upside, equities analysts plainly believe Electromed is more favorable than Baird Medical Investment.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Electromed 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor ELMD or BDMD? In the previous week, Electromed had 3 more articles in the media than Baird Medical Investment. MarketBeat recorded 3 mentions for Electromed and 0 mentions for Baird Medical Investment. Electromed's average media sentiment score of 0.87 beat Baird Medical Investment's score of 0.00 indicating that Electromed is being referred to more favorably in the media. Company Overall Sentiment Electromed Positive Baird Medical Investment Neutral Which has more volatility & risk, ELMD or BDMD? Electromed has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.18, indicating that its share price is 218% less volatile than the broader market. Which has higher earnings and valuation, ELMD or BDMD? Electromed has higher revenue and earnings than Baird Medical Investment. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElectromed$71.75M4.43$5.15M$1.1732.79Baird Medical Investment$22.54M2.98N/AN/AN/A SummaryElectromed beats Baird Medical Investment on 13 of the 14 factors compared between the two stocks.How does Baird Medical Investment compare to Orchestra BioMed?Baird Medical Investment (NASDAQ:BDMD) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment. Does the media refer more to BDMD or OBIO? In the previous week, Orchestra BioMed had 23 more articles in the media than Baird Medical Investment. MarketBeat recorded 23 mentions for Orchestra BioMed and 0 mentions for Baird Medical Investment. Orchestra BioMed's average media sentiment score of 0.67 beat Baird Medical Investment's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Overall Sentiment Baird Medical Investment Neutral Orchestra BioMed Positive Which has stronger earnings and valuation, BDMD or OBIO? Baird Medical Investment has higher earnings, but lower revenue than Orchestra BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBaird Medical Investment$22.54M2.98N/AN/AN/AOrchestra BioMed$33.48M7.15-$52.70M-$0.97N/A Do analysts prefer BDMD or OBIO? Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 240.00%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Baird Medical Investment.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Orchestra BioMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Do insiders and institutionals have more ownership in BDMD or OBIO? 19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, BDMD or OBIO? Baird Medical Investment has a beta of -1.18, indicating that its share price is 218% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Is BDMD or OBIO more profitable? Baird Medical Investment has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Baird Medical Investment's return on equity of 0.00% beat Orchestra BioMed's return on equity.Company Net Margins Return on Equity Return on Assets Baird Medical InvestmentN/A N/A N/A Orchestra BioMed -166.96%-157.46%-60.18% SummaryOrchestra BioMed beats Baird Medical Investment on 9 of the 13 factors compared between the two stocks.How does Baird Medical Investment compare to RxSight?RxSight (NASDAQ:RXST) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability. Which has more volatility & risk, RXST or BDMD? RxSight has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.18, suggesting that its share price is 218% less volatile than the broader market. Do institutionals & insiders have more ownership in RXST or BDMD? 78.8% of RxSight shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is RXST or BDMD more profitable? Baird Medical Investment has a net margin of 0.00% compared to RxSight's net margin of -36.58%. Baird Medical Investment's return on equity of 0.00% beat RxSight's return on equity.Company Net Margins Return on Equity Return on Assets RxSight-36.58% -17.01% -15.12% Baird Medical Investment N/A N/A N/A Which has preferable earnings & valuation, RXST or BDMD? Baird Medical Investment has lower revenue, but higher earnings than RxSight. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRxSight$134.48M1.83-$38.94M-$1.13N/ABaird Medical Investment$22.54M2.98N/AN/AN/A Do analysts prefer RXST or BDMD? RxSight currently has a consensus price target of $9.44, suggesting a potential upside of 58.73%. Given RxSight's stronger consensus rating and higher probable upside, equities analysts plainly believe RxSight is more favorable than Baird Medical Investment.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 3 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor RXST or BDMD? In the previous week, RxSight had 2 more articles in the media than Baird Medical Investment. MarketBeat recorded 2 mentions for RxSight and 0 mentions for Baird Medical Investment. RxSight's average media sentiment score of 0.00 equaled Baird Medical Investment'saverage media sentiment score. Company Overall Sentiment RxSight Neutral Baird Medical Investment Neutral SummaryRxSight beats Baird Medical Investment on 7 of the 12 factors compared between the two stocks. Get Baird Medical Investment News Delivered to You Automatically Sign up to receive the latest news and ratings for BDMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDMD vs. The Competition ExportMetricBaird Medical InvestmentMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.21M$6.99B$6.25B$12.23BDividend YieldN/A1.69%2.80%5.27%P/E RatioN/A40.2517.5422.48Price / Sales2.9870.19531.2172.17Price / CashN/A24.4943.0954.25Price / BookN/A6.249.816.83Net IncomeN/A$158.81M$3.55B$335.69M7 Day Performance-4.09%-1.12%-2.07%-2.03%1 Month Performance-6.82%-5.54%-3.90%-1.90%1 Year Performance-67.97%-4.51%29.39%27.36% Baird Medical Investment Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDMDBaird Medical InvestmentN/A$1.64flatN/A-67.8%$67.21M$22.54MN/AN/AShort Interest DecreaseSGHTSight Sciences4.1877 of 5 stars$4.96+0.6%$8.31+67.6%+36.9%$269.60M$77.36MN/A210PROFProfound Medical1.5504 of 5 stars$7.26+1.7%$12.00+65.3%+46.3%$262.74M$16.10MN/A150ELMDElectromed1.4889 of 5 stars$31.43+15.6%$36.67+16.7%+77.4%$261.20M$68.86M42.09160News CoverageInsider TradeOBIOOrchestra BioMed4.2176 of 5 stars$4.11+1.2%$14.50+253.0%+37.2%$244.91M$33.48MN/A4Trending NewsEarnings ReportAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies SGHT Competitors PROF Competitors ELMD Competitors OBIO Competitors RXST Competitors LUCD Competitors SMTI Competitors EMBC Competitors INGN Competitors PDEX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDMD) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baird Medical Investment Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Baird Medical Investment With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
